共 62 条
[1]
Sung H(2021)GLOBAL cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]
Ferlay J(2017)Clinical and epidemiological profile of breast cancer in Mexico: results of the seguro popular J Glob Oncol 3 757-764
[3]
Siegel RL(2017)20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years N Engl J Med 377 1836-1846
[4]
Laversanne M(2020)5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Ann Oncol 31 1623-1649
[5]
Soerjomataram I(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-1936
[6]
Jemal A(2018)Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer Ann Oncol 29 1541-1547
[7]
Reynoso-Noverón N(2019)MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer NPJ Breast Cancer 5 5-915
[8]
Villarreal-Garza C(2018)Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomized phase 3 trial Lancet Oncol 19 904-1759
[9]
Soto-Perez-de-Celis E(2021)Cost-effectiveness of ribociclib plus letrozole Ther Adv Med Oncol 13 17588359211000593-31
[10]
Arce-Salinas C(2019)Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial Lancet Oncol 20 1750-undefined